Cancel
Andrew Cheng
President & Chief Executive Officer
@
Akero Therapeutics
qvbisb@f00plu4.13j
Sign up to see email
See Linkedin
Known information
- Served for 19 years at Gilead Sciences, where his last role was Chief Medical Officer.
- Was responsible for the clinical development of the HIV program resulting in 11 FDA/EMA approved products.
- Serves on the board of directors of Vera Therapeutics and MorphoSys.
- Previously served on the board of directors of Arbutus Biopharma and privately held Syntimmune, which was acquired by Alexion.
- Holds a B.A. in biology from Johns Hopkins University.
- Holds an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons.
- Completed his internal medicine residency at UCLA.
- Was board certified in internal medicine.
About Akero Therapeutics
Akero Therapeutics, founded in 2017 and headquartered in South San Francisco, pioneers novel therapies for serious metabolic diseases, focusing on Efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH). EFX, an Fc-FGF21 fusion protein, has shown potential in reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipids.
Report inaccurate information
